⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL277241 | 0.77 | — | — | |
| SCHEMBL276841 | 0.75 | — | — | |
| SCHEMBL553596 | 0.73 | TDP1 (0.38) | — | |
| SCHEMBL429953 | 0.73 | FFAR3 (0.41) | — | |
| SCHEMBL993023 | 0.73 | — | — | |
| SCHEMBL5580381 | 0.73 | — | — | |
| SCHEMBL994194 | 0.73 | — | — | |
| SCHEMBL8847814 | 0.73 | GGPS1 (0.37) | — | |
| SCHEMBL269270 | 0.71 | — | — | |
| SCHEMBL276549 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 311 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114867525-A | Dihydrocyclopentaisoquinoline derivatives | UCB生物制药有限责任公司 | 2022-08-05 | — | — | CN | claimed |
| EP-1906945-B1 | HCV INHIBITORS | VIROBAY INC (US) | 2015-08-05 | — | — | EP | claimed |
| EP-2431379-A2 | HCV inhibitors | Virobay, Inc. (US) | 2012-03-21 | — | — | EP | claimed |
| US-20100279936-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2010-11-04 | — | — | US | claimed |
| US-20100266537-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2010-10-21 | — | — | US | claimed |
| US-7608592-B2 | HCV inhibitors | VIROBAY, INC. (US) | 2009-10-27 | — | — | US | claimed |
| EP-1906945-A4 | HCV INHIBITORS | VIROBAY INC (US) | 2009-07-15 | — | — | EP | claimed |
| EP-2061449-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | Leo Pharma A/S (DK) | 2009-05-27 | — | — | EP | claimed |
| WO-2008086053-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-17 | — | — | WO | claimed |
| US-20080161254-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-03 | — | — | US | claimed |
| EP-1906945-A2 | HCV INHIBITORS | Virobay, Inc. (US) | 2008-04-09 | — | — | EP | claimed |
| WO-2008019690-A1 | SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES | LEO PHARMA A/S (DK) | 2008-02-21 | — | — | WO | claimed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | claimed |
| WO-2007005838-A2 | HCV INHIBITORS | VIROBAY, INC. (US) | 2007-01-11 | — | — | WO | claimed |
| CN-114026199-B | Polarized light emitting film, polarized light emitting panel and display device containing water-soluble coumarin compound or salt thereof | 日本化药株式会社 | 2023-12-26 | — | — | CN | disclosed |
| CN-116813979-A | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-09-29 | — | — | CN | disclosed |
| CN-112839988-B | Nucleating agent, synthetic resin composition containing same, and molded article thereof | 株式会社ADEKA | 2023-06-06 | — | — | CN | disclosed |
| EP-0453883-A2 | 2-amino-4-trichloropyridine derivatives | BASF Aktiengesellschaft (DE) | 1991-10-30 | — | — | EP | disclosed |
| US-4616015-A | HYPOTENSIVE AGENT, ANTULCER AGENT, ANTICOAGULANT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-07 | — | — | US | disclosed |
| EP-0122627-A2 | Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-10-24 | — | — | EP | disclosed |